Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00199849 · ClinicalTrials.gov registry record · Phase 1
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
A Phase 1 study, sponsored by Ludwig Institute for Cancer Research.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00199849 is a Phase 1 study that has completed, run by Ludwig Institute for Cancer Research. The registered enrollment target is 18 participants.
The verdict
NCT00199849, a Phase 1 study, has completed, sponsored by Ludwig Institute for Cancer Research.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
To evaluate the safety of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine given by particle-mediated epidermal delivery (PMED) in patients with tumor types known to express NY-ESO-1 or LAGE-1.
Interventions
- BIOLOGICAL NY-ESO-1 Plasmid DNA Cancer Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2004-09-27 |
| Est. Completion | 2007-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00199849
The ClinicalTrials.gov registry entry for NCT00199849 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ludwig Institute for Cancer Research, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NY-ESO-1 Plasmid DNA Cancer Vaccine is the first listed.
NCT00199849 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00199849 about?
NCT00199849 is a clinical study titled "NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine". To evaluate the safety of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine given by particle-mediated epidermal delivery (PMED) in patients with tumor types known to express NY-ESO-1 or LAGE-1.
What is the current status of trial NCT00199849?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2004-09-27. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00199849?
The interventions under investigation include: NY-ESO-1 Plasmid DNA Cancer Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00199849?
This trial is sponsored by Ludwig Institute for Cancer Research, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.